A new synthesis finds that common epilepsies are driven by thousands of tiny-effect genetic variants, most still ...
An insightful mini-review published in Genomic Psychiatry synthesizes the rapidly expanding landscape of molecular genetic research on common epilepsies, assembling evidence from genome-wide ...
RAP-219’s lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of ...
RAP-219's lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026RA ...
Biohaven Ltd BHVN shares were trading higher on Monday during the premarket session at as high as $12.52, before falling. The ...
The company reiterated "full year 2026 revenue guidance of $98 million to $100 million," assuming "underlying core RNS growth of 20% to 22% within our current adult focal epilepsy indication and ...
Medicinal cannabis might be increasingly available in many parts of the world, but a new review suggests it has no ...
Partnership leverages Tenacia’s expertise in central nervous system (CNS) drug development and commercialization to accelerate U.S. and global ...
Thank you, operator, and welcome to NeuroPace's fourth quarter and full year 2025 earnings conference call. Our agenda begins with Joel B ...
NeuroPace Inc (NPCE) reports robust revenue growth and positive EBITDA, while navigating challenges and advancing its AI-driven product pipeline.
NeuroPace (NASDAQ:NPCE) reported fourth-quarter and full-year 2025 results that management said reflected sustained momentum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results